Alzheimer Disease Blood-Based Diagnostics Market (2026-2036)

The Alzheimer disease blood-based diagnostics market covers plasma assays measuring phosphorylated tau at residue 217 and at residue 181, the ratio of amyloid beta 42 to amyloid beta 40, combined tau and amyloid ratios, glial fibrillary acidic protein and neurofilament light, supplied as cleared in vitro diagnostics, as laboratory developed tests and for research use. The growth of this market is driven by clearance of the first blood tests for this purpose, by a clinical practice guideline that sets numeric performance thresholds, by amyloid confirmation being required before anti-amyloid therapy, and by clearance extending into primary care.

The FDA cleared the Lumipulse G pTau217/beta-Amyloid 1-42 Plasma Ratio from Fujirebio Diagnostics, Inc. on 16 May 2025, the first blood test cleared to aid in diagnosing Alzheimer disease by detecting amyloid plaques early in adults aged 55 and older who show signs and symptoms of the disease, intended for patients in specialised care settings with signs of cognitive decline and not as a standalone or screening test, with a clinical study of 499 plasma samples from cognitively impaired adults showing that 91.7% of those with a positive result had amyloid plaques confirmed by amyloid PET or cerebrospinal fluid testing, that 97.3% of those with a negative result had negative amyloid PET or cerebrospinal fluid results, and that fewer than 20% received an indeterminate result. Clearance of a blood test for a disease previously confirmed only by amyloid imaging or lumbar puncture establishes the category, and the explicit exclusion of screening use defines where the revenue can and cannot arise.

The Alzheimer Association clinical practice guideline on blood-based biomarkers applies to specialty care settings including neurology, geriatrics, psychiatry and memory clinics, and to patients with objective cognitive impairment presenting for specialised memory care. It recommends, as a conditional recommendation on low-certainty evidence, that a test used for triage reach sensitivity above 90% and specificity above 75%, in which case a negative result rules out Alzheimer pathology while a positive result requires confirmation by amyloid PET or cerebrospinal fluid analysis, and that a test used for confirmation reach sensitivity above 90% and specificity above 90%, in which case a negative result rules the pathology out and a positive result rules it in. The two thresholds divide the market rather than grading it, because a test that meets the triage standard leaves every positive result requiring confirmatory imaging or cerebrospinal fluid analysis, so imaging volumes do not fall, while a test that reaches the confirmatory standard removes that step entirely. Specificity above 90% rather than clearance is therefore what changes the economics of the pathway.

Amyloid pathology in Alzheimer disease was confirmed for two decades only by positron emission tomography with an amyloid tracer or by measuring amyloid and tau proteins in cerebrospinal fluid obtained by lumbar puncture. One requires a cyclotron-supplied tracer, a scanner and a reimbursement decision, the other requires a procedure patients decline and clinicians are reluctant to perform, and both are available in a limited number of centres, which is why most patients with cognitive symptoms were never tested for the pathology at all.

The FDA cleared the Lumipulse G pTau217/beta-Amyloid 1-42 Plasma Ratio from Fujirebio Diagnostics, Inc. on 16 May 2025, the first blood test cleared to aid in diagnosing Alzheimer disease by detecting amyloid plaques early in adults aged 55 and older who show signs and symptoms of the disease, intended for patients in specialised care settings with signs of cognitive decline and not as a standalone or screening test, with a clinical study of 499 plasma samples from cognitively impaired adults showing that 91.7% of those with a positive result had amyloid plaques confirmed by amyloid PET or cerebrospinal fluid testing, that 97.3% of those with a negative result had negative amyloid PET or cerebrospinal fluid results, and that fewer than 20% received an indeterminate result. Measuring phosphorylated tau and amyloid beta in plasma at concentrations orders of magnitude below those in cerebrospinal fluid became possible through improved antibodies, mass spectrometry and ultrasensitive immunoassay platforms, and clearance confirmed that the analytical performance reached a standard a regulator would accept for a diagnostic claim.

The Alzheimer Association clinical practice guideline on blood-based biomarkers applies to specialty care settings including neurology, geriatrics, psychiatry and memory clinics, and to patients with objective cognitive impairment presenting for specialised memory care. It recommends, as a conditional recommendation on low-certainty evidence, that a test used for triage reach sensitivity above 90% and specificity above 75%, in which case a negative result rules out Alzheimer pathology while a positive result requires confirmation by amyloid PET or cerebrospinal fluid analysis, and that a test used for confirmation reach sensitivity above 90% and specificity above 90%, in which case a negative result rules the pathology out and a positive result rules it in. A test meeting only the triage standard still sends every positive patient to amyloid imaging or lumbar puncture, so the blood test adds cost and removes none, while a test reaching the confirmatory standard replaces that step. The commercial value of a blood test therefore sits in the specificity it achieves rather than in the fact of clearance, and the difference between 75% and 90% specificity is the difference between an additional test and a substituted one.

Roche Diagnostics reported on 24 August 2026 that the FDA had cleared the Elecsys Phospho-Tau (217P) Plasma single-biomarker blood test, developed in collaboration with Eli Lilly and Company, to aid assessment of amyloid pathology associated with Alzheimer disease in individuals aged 55 and older with signs, symptoms or complaints of cognitive decline, returning positive, intermediate or negative result categories and using the same validated clinical cutoffs in primary care as in specialty care. Validated cutoffs that hold in primary care remove the specialist referral from the pathway for the patients a negative result excludes, which is a far larger population than the one reaching memory clinics, and it is the development that converts this from a specialty diagnostic into a widely used one.

The first cleared test reported fewer than 20% of 499 patients receiving an indeterminate result, so up to one patient in five obtains no answer and proceeds to imaging or lumbar puncture regardless, and the second cleared test returns positive, intermediate or negative categories rather than a binary result. The cost case for replacing confirmatory testing therefore has to be built on the proportion of patients a test resolves rather than on its sensitivity and specificity in those it does.

Anti-amyloid monoclonal antibodies require confirmed amyloid pathology before treatment can begin, which created a confirmation requirement that amyloid imaging and lumbar puncture capacity cannot meet, and patients waited months for a scan that determined whether they were eligible. A blood test that resolves most of those patients without imaging addresses a bottleneck with a defined and funded clinical consequence.

Most testing volume today is supplied as laboratory developed tests rather than as cleared products, because laboratories offered plasma assays before any clearance existed and continue to do so. Those tests operate under enforcement discretion in the United States, so a laboratory can offer one without demonstrating analytical or clinical validity to a regulator, and performance between providers varies in ways a clinician receiving a result cannot assess.

A cleared test with a guideline recommendation and a procedure code is paid for, a laboratory developed test with equivalent performance may not be, and coverage for use in patients without cognitive impairment does not exist because no guideline recommends testing that population. The revenue available is therefore confined to symptomatic patients being assessed, whatever the test can technically detect.

The first cleared test is explicitly not a screening test, the guideline addresses only patients with objective cognitive impairment, and no recommendation covers people without symptoms, so detecting amyloid pathology in a person who feels well has no established pathway, no reimbursement and no agreed action following a positive result.

Platform placement determines who captures the volume, since a cleared assay runs on the analysers a manufacturer has already installed in clinical laboratories, and a laboratory running one supplier immunoassay system does not change platforms for a single assay. The companies with the largest installed base of automated immunoassay analysers therefore reach the most laboratories, which matters more than assay performance within the range that meets the guideline thresholds. A laboratory already running a manufacturer analyser can add the assay as a menu item, which is a purchasing decision rather than an adoption decision. A supplier without that base has to place an instrument before it can sell a test, and a laboratory will not accept one for a single assay however good it is.